{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T22:45:05Z","timestamp":1792104305364,"version":"4.4.0"},"reference-count":135,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:00:00Z","timestamp":1763596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:00:00Z","timestamp":1763596800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Capital\u2019s Funds for Health Improvement and Research","award":["2022\u20132-4131"],"award-info":[{"award-number":["2022\u20132-4131"]}]},{"name":"Capital\u2019s Funds for Health Improvement and Research","award":["2024\u20132-4131"],"award-info":[{"award-number":["2024\u20132-4131"]}]},{"name":"Priority Project of the Beijing Municipal TCM Science and Technology Development Fund","award":["BJZYZD-2023\u201301"],"award-info":[{"award-number":["BJZYZD-2023\u201301"]}]},{"name":"National TCM Advantage Specialty Construction Unit, National Administration of Traditional Chinese Medicine"},{"name":"Young Elite Scientists Sponsorship Program by China Association for Science and Technology","award":["2023QNRC001"],"award-info":[{"award-number":["2023QNRC001"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Obes Rep"],"DOI":"10.1007\/s13679-025-00673-5","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T03:57:40Z","timestamp":1763611060000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Beyond Discrete Diagnoses: Conceptualizing Obesity-associated Metabolic Disorders as a Unified, Dynamic Continuum"],"prefix":"10.1007","volume":"14","author":[{"given":"Cong","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulian","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunjing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuan","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aifeila","family":"Aikepaer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaofu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ge","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingzhong","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijuan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,20]]},"reference":[{"issue":"10440","key":"673_CR1","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1016\/S0140-6736(24)00933-4","volume":"403","author":"Collaborators GBDRF","year":"2024","unstructured":"Collaborators GBDRF. Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990\u20132021: a systematic analysis for the global burden of disease study 2021. Lancet. 2024;403(10440):2162\u2013203. https:\/\/doi.org\/10.1016\/S0140-6736(24)00933-4.","journal-title":"Lancet"},{"key":"673_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2021.109119","volume":"183","author":"H Sun","year":"2022","unstructured":"Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, et al. IDF diabetes atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022;183:109119. https:\/\/doi.org\/10.1016\/j.diabres.2021.109119.","journal-title":"Diabetes Res Clin Pract"},{"key":"673_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s13098-020-00570-y","volume":"12","author":"AF Godoy-Matos","year":"2020","unstructured":"Godoy-Matos AF, Silva Junior WS, Valerio CM. Nafld as a continuum: from obesity to metabolic syndrome and diabetes. Diabetol Metab Syndr. 2020;12:60. https:\/\/doi.org\/10.1186\/s13098-020-00570-y.","journal-title":"Diabetol Metab Syndr"},{"issue":"1","key":"673_CR4","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/hep.29367","volume":"67","author":"N Chalasani","year":"2018","unstructured":"Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American association for the study of liver diseases. Hepatology. 2018;67(1):328\u201357. https:\/\/doi.org\/10.1002\/hep.29367.","journal-title":"Hepatology"},{"issue":"1","key":"673_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-023-04639-w","volume":"21","author":"A Amouzegar","year":"2023","unstructured":"Amouzegar A, Honarvar M, Masoumi S, Khalili D, Azizi F, Mehran L. Trajectory patterns of metabolic syndrome severity score and risk of type 2 diabetes. J Transl Med. 2023;21(1):750. https:\/\/doi.org\/10.1186\/s12967-023-04639-w.","journal-title":"J Transl Med"},{"key":"673_CR6","doi-asserted-by":"publisher","first-page":"110699","DOI":"10.1016\/j.diabres.2023.110699","volume":"200","author":"Y Gao","year":"2023","unstructured":"Gao Y, Zhao T, Song S, Duo Y, Gao J, Yuan T, et al. Lean nonalcoholic fatty liver disease and risk of incident type 2 diabetes mellitus: A literature review and meta-analysis. Diabetes Res Clin Pract. 2023;200:110699. https:\/\/doi.org\/10.1016\/j.diabres.2023.110699.","journal-title":"Diabetes Res Clin Pract"},{"issue":"4","key":"673_CR7","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","volume":"71","author":"ZM Younossi","year":"2019","unstructured":"Younossi ZM, Golabi P, de Avila L, Paik JM, Srishord M, Fukui N, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J Hepatol. 2019;71(4):793\u2013801. https:\/\/doi.org\/10.1016\/j.jhep.2019.06.021.","journal-title":"J Hepatol"},{"issue":"1","key":"673_CR8","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73\u201384. https:\/\/doi.org\/10.1002\/hep.28431.","journal-title":"Hepatology"},{"issue":"13","key":"673_CR9","doi-asserted-by":"publisher","first-page":"5691","DOI":"10.7150\/ijbs.117211","volume":"21","author":"M Kang","year":"2025","unstructured":"Kang M, Song J, Kang ES, Jang S, Kwak T, Kim Y, et al. Pathophysiology, development, and mortality of major non-communicable diseases in metabolic dysfunction-associated steatotic liver disease: a comprehensive review. Int J Biol Sci. 2025;21(13):5691\u2013703. https:\/\/doi.org\/10.7150\/ijbs.117211.","journal-title":"Int J Biol Sci"},{"issue":"12","key":"673_CR10","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1056\/NEJMra1011035","volume":"371","author":"GI Shulman","year":"2014","unstructured":"Shulman GI. Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease. N Engl J Med. 2014;371(12):1131\u201341. https:\/\/doi.org\/10.1056\/NEJMra1011035.","journal-title":"N Engl J Med"},{"issue":"4","key":"673_CR11","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.cmet.2021.03.020","volume":"33","author":"L Sylow","year":"2021","unstructured":"Sylow L, Tokarz VL, Richter EA, Klip A. The many actions of insulin in skeletal muscle, the paramount tissue determining glycemia. Cell Metab. 2021;33(4):758\u201380. https:\/\/doi.org\/10.1016\/j.cmet.2021.03.020.","journal-title":"Cell Metab"},{"issue":"4","key":"673_CR12","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1002\/hep.29094","volume":"65","author":"Y Rotman","year":"2017","unstructured":"Rotman Y, Neuschwander-Tetri BA. Liver fat accumulation as a barometer of insulin responsiveness again points to adipose tissue as the culprit. Hepatology. 2017;65(4):1088\u201390. https:\/\/doi.org\/10.1002\/hep.29094.","journal-title":"Hepatology"},{"issue":"3","key":"673_CR13","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1210\/er.2007-0023","volume":"29","author":"V Poitout","year":"2008","unstructured":"Poitout V, Robertson RP. Glucolipotoxicity: fuel excess and beta-cell dysfunction. Endocr Rev. 2008;29(3):351\u201366. https:\/\/doi.org\/10.1210\/er.2007-0023.","journal-title":"Endocr Rev"},{"issue":"Suppl 3","key":"673_CR14","doi-asserted-by":"publisher","first-page":"S16","DOI":"10.2337\/diabetes.53.suppl_3.s16","volume":"53","author":"GC Weir","year":"2004","unstructured":"Weir GC, Bonner-Weir S. Five stages of evolving beta-cell dysfunction during progression to diabetes. Diabetes. 2004;53(Suppl 3):S16\u201321. https:\/\/doi.org\/10.2337\/diabetes.53.suppl_3.s16.","journal-title":"Diabetes"},{"issue":"7","key":"673_CR15","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1007\/s00125-025-06428-0","volume":"68","author":"R Taylor","year":"2025","unstructured":"Taylor R. Aetiology of type 2 diabetes: an experimental medicine odyssey. Diabetologia. 2025;68(7):1375\u201389. https:\/\/doi.org\/10.1007\/s00125-025-06428-0.","journal-title":"Diabetologia"},{"issue":"4","key":"673_CR16","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1152\/physrev.00063.2017","volume":"98","author":"MC Petersen","year":"2018","unstructured":"Petersen MC, Shulman GI. Mechanisms of insulin action and insulin resistance. Physiol Rev. 2018;98(4):2133\u2013223. https:\/\/doi.org\/10.1152\/physrev.00063.2017.","journal-title":"Physiol Rev"},{"issue":"11","key":"673_CR17","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1055\/s-0031-1286305","volume":"43","author":"IM Olivares-Corichi","year":"2011","unstructured":"Olivares-Corichi IM, Viquez MJ, Gutierrez-Lopez L, Ceballos-Reyes GM, Garcia-Sanchez JR. Oxidative stress present in the blood from obese patients modifies the structure and function of insulin. Horm Metab Res. 2011;43(11):748\u201353. https:\/\/doi.org\/10.1055\/s-0031-1286305.","journal-title":"Horm Metab Res"},{"issue":"1","key":"673_CR18","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1172\/JCI29881","volume":"117","author":"CN Lumeng","year":"2007","unstructured":"Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest. 2007;117(1):175\u201384. https:\/\/doi.org\/10.1172\/JCI29881.","journal-title":"J Clin Invest"},{"issue":"7121","key":"673_CR19","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/nature05485","volume":"444","author":"GS Hotamisligil","year":"2006","unstructured":"Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006;444(7121):860\u20137. https:\/\/doi.org\/10.1038\/nature05485.","journal-title":"Nature"},{"issue":"2","key":"673_CR20","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/s41575-019-0210-2","volume":"17","author":"S Sutti","year":"2020","unstructured":"Sutti S, Albano E. Adaptive immunity: an emerging player in the progression of NAFLD. Nat Rev Gastroenterol Hepatol. 2020;17(2):81\u201392. https:\/\/doi.org\/10.1038\/s41575-019-0210-2.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"5","key":"673_CR21","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.cmet.2012.04.001","volume":"15","author":"CK Glass","year":"2012","unstructured":"Glass CK, Olefsky JM. Inflammation and lipid signaling in the etiology of insulin resistance. Cell Metab. 2012;15(5):635\u201345. https:\/\/doi.org\/10.1016\/j.cmet.2012.04.001.","journal-title":"Cell Metab"},{"key":"673_CR22","doi-asserted-by":"publisher","unstructured":"de Assis GG, Murawska-Cialowicz E. Leptin-A Potential Bridge between Fat Metabolism and the Brain\u2019s Vulnerability to Neuropsychiatric Disorders: A Systematic Review. J Clin Med. 2021;10(23). https:\/\/doi.org\/10.3390\/jcm10235714.","DOI":"10.3390\/jcm10235714"},{"issue":"1","key":"673_CR23","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1590\/1806-9282.61.01.072","volume":"61","author":"GA Balsan","year":"2015","unstructured":"Balsan GA, Vieira JL, Oliveira AM, Portal VL. Relationship between adiponectin, obesity and insulin resistance. Rev Assoc Med Bras (1992). 2015;61(1):72\u201380. https:\/\/doi.org\/10.1590\/1806-9282.61.01.072.","journal-title":"Rev Assoc Med Bras (1992)"},{"key":"673_CR24","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1146\/annurev.physiol.70.113006.100707","volume":"70","author":"MG Myers","year":"2008","unstructured":"Myers MG, Cowley MA, Munzberg H. Mechanisms of leptin action and leptin resistance. Annu Rev Physiol. 2008;70:537\u201356. https:\/\/doi.org\/10.1146\/annurev.physiol.70.113006.100707.","journal-title":"Annu Rev Physiol"},{"issue":"3","key":"673_CR25","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1210\/er.2005-0005","volume":"26","author":"T Kadowaki","year":"2005","unstructured":"Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev. 2005;26(3):439\u201351. https:\/\/doi.org\/10.1210\/er.2005-0005.","journal-title":"Endocr Rev"},{"key":"673_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2024.1362731","volume":"11","author":"F Kazeminasab","year":"2024","unstructured":"Kazeminasab F, Behzadnejad N, Cerqueira HS, Santos HO, Rosenkranz SK. Effects of intermittent fasting combined with exercise on serum leptin and adiponectin in adults with or without obesity: a systematic review and meta-analysis of randomized clinical trials. Front Nutr. 2024;11:1362731. https:\/\/doi.org\/10.3389\/fnut.2024.1362731.","journal-title":"Front Nutr"},{"key":"673_CR27","doi-asserted-by":"publisher","unstructured":"Flores-Cortez YA, Barragan-Bonilla MI, Mendoza-Bello JM, Gonzalez-Calixto C, Flores-Alfaro E, Espinoza-Rojo M. Interplay of retinol binding protein 4 with obesity and associated chronic alterations (Review). Mol Med Rep. 2022;26(1). https:\/\/doi.org\/10.3892\/mmr.2022.12760.","DOI":"10.3892\/mmr.2022.12760"},{"issue":"7049","key":"673_CR28","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/nature03711","volume":"436","author":"Q Yang","year":"2005","unstructured":"Yang Q, Graham TE, Mody N, Preitner F, Peroni OD, Zabolotny JM, et al. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature. 2005;436(7049):356\u201362. https:\/\/doi.org\/10.1038\/nature03711.","journal-title":"Nature"},{"issue":"3","key":"673_CR29","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.cmet.2014.01.018","volume":"19","author":"PM Moraes-Vieira","year":"2014","unstructured":"Moraes-Vieira PM, Yore MM, Dwyer PM, Syed I, Aryal P, Kahn BB. RBP4 activates antigen-presenting cells, leading to adipose tissue inflammation and systemic insulin resistance. Cell Metab. 2014;19(3):512\u201326. https:\/\/doi.org\/10.1016\/j.cmet.2014.01.018.","journal-title":"Cell Metab"},{"key":"673_CR30","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.molmet.2018.05.006","volume":"13","author":"A Girousse","year":"2018","unstructured":"Girousse A, Virtue S, Hart D, Vidal-Puig A, Murgatroyd PR, Mouisel E, et al. Surplus fat rapidly increases fat oxidation and insulin resistance in lipodystrophic mice. Mol Metab. 2018;13:24\u20139. https:\/\/doi.org\/10.1016\/j.molmet.2018.05.006.","journal-title":"Mol Metab"},{"key":"673_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/nu15102254","author":"GA Bray","year":"2023","unstructured":"Bray GA. Beyond BMI. Nutrients. 2023. https:\/\/doi.org\/10.3390\/nu15102254.","journal-title":"Nutrients"},{"key":"673_CR32","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.metabol.2018.11.014","volume":"92","author":"SA Polyzos","year":"2019","unstructured":"Polyzos SA, Kountouras J, Mantzoros CS. Obesity and nonalcoholic fatty liver disease: from pathophysiology to therapeutics. Metabolism. 2019;92:82\u201397. https:\/\/doi.org\/10.1016\/j.metabol.2018.11.014.","journal-title":"Metabolism"},{"issue":"3","key":"673_CR33","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1053\/j.gastro.2013.11.049","volume":"146","author":"JE Lambert","year":"2014","unstructured":"Lambert JE, Ramos-Roman MA, Browning JD, Parks EJ. Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease. Gastroenterology. 2014;146(3):726\u201335. https:\/\/doi.org\/10.1053\/j.gastro.2013.11.049.","journal-title":"Gastroenterology"},{"issue":"1","key":"673_CR34","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1161\/ATVBAHA.107.147538","volume":"28","author":"A Kotronen","year":"2008","unstructured":"Kotronen A, Yki-Jarvinen H. Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol. 2008;28(1):27\u201338. https:\/\/doi.org\/10.1161\/ATVBAHA.107.147538.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"673_CR35","doi-asserted-by":"publisher","first-page":"154770","DOI":"10.1016\/j.metabol.2021.154770","volume":"119","author":"E Muzurovic","year":"2021","unstructured":"Muzurovic E, Mikhailidis DP, Mantzoros C. Non-alcoholic fatty liver disease, insulin resistance, metabolic syndrome and their association with vascular risk. Metabolism. 2021;119:154770. https:\/\/doi.org\/10.1016\/j.metabol.2021.154770.","journal-title":"Metabolism"},{"issue":"1\u20132","key":"673_CR36","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.mce.2012.04.013","volume":"378","author":"E Matthew Morris","year":"2013","unstructured":"Matthew Morris E, Fletcher JA, Thyfault JP, Rector RS. The role of angiotensin II in nonalcoholic steatohepatitis. Mol Cell Endocrinol. 2013;378(1\u20132):29\u201340. https:\/\/doi.org\/10.1016\/j.mce.2012.04.013.","journal-title":"Mol Cell Endocrinol"},{"issue":"2","key":"673_CR37","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1161\/HYPERTENSIONAHA.119.13419","volume":"75","author":"YC Zhao","year":"2020","unstructured":"Zhao YC, Zhao GJ, Chen Z, She ZG, Cai J, Li H. Nonalcoholic fatty liver disease: an emerging driver of hypertension. Hypertension. 2020;75(2):275\u201384. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.119.13419.","journal-title":"Hypertension"},{"issue":"2","key":"673_CR38","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1097\/MCG.0000000000000666","volume":"51","author":"R Jinjuvadia","year":"2017","unstructured":"Jinjuvadia R, Antaki F, Lohia P, Liangpunsakul S. The association between nonalcoholic fatty liver disease and metabolic abnormalities in the united States population. J Clin Gastroenterol. 2017;51(2):160\u20136. https:\/\/doi.org\/10.1097\/MCG.0000000000000666.","journal-title":"J Clin Gastroenterol"},{"issue":"9","key":"673_CR39","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.2337\/dc08-0423","volume":"31","author":"ES Ford","year":"2008","unstructured":"Ford ES, Li C, Sattar N. Metabolic syndrome and incident diabetes: current state of the evidence. Diabetes Care. 2008;31(9):1898\u2013904. https:\/\/doi.org\/10.2337\/dc08-0423.","journal-title":"Diabetes Care"},{"issue":"2","key":"673_CR40","doi-asserted-by":"publisher","first-page":"372","DOI":"10.2337\/dc17-1902","volume":"41","author":"A Mantovani","year":"2018","unstructured":"Mantovani A, Byrne CD, Bonora E, Targher G. Nonalcoholic fatty liver disease and risk of incident type 2 diabetes: a meta-analysis. Diabetes Care. 2018;41(2):372\u201382. https:\/\/doi.org\/10.2337\/dc17-1902.","journal-title":"Diabetes Care"},{"issue":"5","key":"673_CR41","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1136\/gutjnl-2020-322572","volume":"70","author":"A Mantovani","year":"2021","unstructured":"Mantovani A, Petracca G, Beatrice G, Tilg H, Byrne CD, Targher G. Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals. Gut. 2021;70(5):962\u20139. https:\/\/doi.org\/10.1136\/gutjnl-2020-322572.","journal-title":"Gut"},{"issue":"4","key":"673_CR42","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.jcmgh.2019.02.001","volume":"7","author":"CC Duwaerts","year":"2019","unstructured":"Duwaerts CC, Maher JJ. Macronutrients and the adipose-liver axis in obesity and fatty liver. Cell Mol Gastroenterol Hepatol. 2019;7(4):749\u201361. https:\/\/doi.org\/10.1016\/j.jcmgh.2019.02.001.","journal-title":"Cell Mol Gastroenterol Hepatol"},{"issue":"4","key":"673_CR43","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1007\/s10787-021-00837-4","volume":"29","author":"O Sardana","year":"2021","unstructured":"Sardana O, Goyal R, Bedi O. Molecular and pathobiological involvement of fetuin-A in the pathogenesis of NAFLD. Inflammopharmacology. 2021;29(4):1061\u201374. https:\/\/doi.org\/10.1007\/s10787-021-00837-4.","journal-title":"Inflammopharmacology"},{"issue":"5","key":"673_CR44","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1210\/er.2018-00251","volume":"40","author":"NJ Wewer Albrechtsen","year":"2019","unstructured":"Wewer Albrechtsen NJ, Pedersen J, Galsgaard KD, Winther-Sorensen M, Suppli MP, Janah L, et al. The Liver-alpha-Cell axis and type 2 diabetes. Endocr Rev. 2019;40(5):1353\u201366. https:\/\/doi.org\/10.1210\/er.2018-00251.","journal-title":"Endocr Rev"},{"issue":"6","key":"673_CR45","doi-asserted-by":"publisher","first-page":"R267","DOI":"10.1530\/EJE-18-0197","volume":"178","author":"FK Knop","year":"2018","unstructured":"Knop FK. EJE PRIZE 2018: A gut feeling about glucagon. Eur J Endocrinol. 2018;178(6):R267\u201380. https:\/\/doi.org\/10.1530\/EJE-18-0197.","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"673_CR46","doi-asserted-by":"publisher","first-page":"235","DOI":"10.2337\/db16-0994","volume":"66","author":"JJ Holst","year":"2017","unstructured":"Holst JJ, Wewer Albrechtsen NJ, Pedersen J, Knop FK. Glucagon and amino acids are linked in a mutual feedback cycle: the Liver-alpha-Cell axis. Diabetes. 2017;66(2):235\u201340. https:\/\/doi.org\/10.2337\/db16-0994.","journal-title":"Diabetes"},{"issue":"6","key":"673_CR47","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1016\/j.cmet.2017.05.011","volume":"25","author":"ED Dean","year":"2017","unstructured":"Dean ED, Li M, Prasad N, Wisniewski SN, Von Deylen A, Spaeth J, et al. Interrupted glucagon signaling reveals hepatic alpha cell axis and role for L-Glutamine in alpha cell proliferation. Cell Metab. 2017;25(6):1362\u2013e735. https:\/\/doi.org\/10.1016\/j.cmet.2017.05.011.","journal-title":"Cell Metab"},{"issue":"5","key":"673_CR48","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1111\/joim.12462","volume":"279","author":"AE Junker","year":"2016","unstructured":"Junker AE, Gluud L, Holst JJ, Knop FK, Vilsboll T. Diabetic and nondiabetic patients with nonalcoholic fatty liver disease have an impaired incretin effect and fasting hyperglucagonaemia. J Intern Med. 2016;279(5):485\u201393. https:\/\/doi.org\/10.1111\/joim.12462.","journal-title":"J Intern Med"},{"issue":"1","key":"673_CR49","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.jcjd.2014.03.002","volume":"39","author":"O Aouacheri","year":"2015","unstructured":"Aouacheri O, Saka S, Krim M, Messaadia A, Maidi I. The investigation of the oxidative stress-related parameters in type 2 diabetes mellitus. Can J Diabetes. 2015;39(1):44\u20139. https:\/\/doi.org\/10.1016\/j.jcjd.2014.03.002.","journal-title":"Can J Diabetes"},{"issue":"7086","key":"673_CR50","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1038\/nature04634","volume":"440","author":"N Houstis","year":"2006","unstructured":"Houstis N, Rosen ED, Lander ES. Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature. 2006;440(7086):944\u20138. https:\/\/doi.org\/10.1038\/nature04634.","journal-title":"Nature"},{"issue":"12","key":"673_CR51","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1172\/JCI21625","volume":"114","author":"S Furukawa","year":"2004","unstructured":"Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y, et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest. 2004;114(12):1752\u201361. https:\/\/doi.org\/10.1172\/JCI21625.","journal-title":"J Clin Invest"},{"issue":"1","key":"673_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.mito.2005.10.004","volume":"6","author":"K Begriche","year":"2006","unstructured":"Begriche K, Igoudjil A, Pessayre D, Fromenty B. Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it. Mitochondrion. 2006;6(1):1\u201328. https:\/\/doi.org\/10.1016\/j.mito.2005.10.004.","journal-title":"Mitochondrion"},{"issue":"5","key":"673_CR53","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1210\/er.2001-0039","volume":"23","author":"JL Evans","year":"2002","unstructured":"Evans JL, Goldfine ID, Maddux BA, Grodsky GM. Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr Rev. 2002;23(5):599\u2013622. https:\/\/doi.org\/10.1210\/er.2001-0039.","journal-title":"Endocr Rev"},{"issue":"1","key":"673_CR54","doi-asserted-by":"publisher","first-page":"8","DOI":"10.2337\/diabetes.54.1.8","volume":"54","author":"VB Ritov","year":"2005","unstructured":"Ritov VB, Menshikova EV, He J, Ferrell RE, Goodpaster BH, Kelley DE. Deficiency of subsarcolemmal mitochondria in obesity and type 2 diabetes. Diabetes. 2005;54(1):8\u201314. https:\/\/doi.org\/10.2337\/diabetes.54.1.8.","journal-title":"Diabetes"},{"issue":"1","key":"673_CR55","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-023-04367-1","volume":"21","author":"Y Zheng","year":"2023","unstructured":"Zheng Y, Wang S, Wu J, Wang Y. Mitochondrial metabolic dysfunction and non-alcoholic fatty liver disease: new insights from pathogenic mechanisms to clinically targeted therapy. J Transl Med. 2023;21(1):510. https:\/\/doi.org\/10.1186\/s12967-023-04367-1.","journal-title":"J Transl Med"},{"issue":"6","key":"673_CR56","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/j.jhep.2005.03.004","volume":"42","author":"D Pessayre","year":"2005","unstructured":"Pessayre D, Fromenty B. NASH: A mitochondrial disease. J Hepatol. 2005;42(6):928\u201340. https:\/\/doi.org\/10.1016\/j.jhep.2005.03.004.","journal-title":"J Hepatol"},{"key":"673_CR57","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.freeradbiomed.2024.01.008","volume":"213","author":"JL Garcia-Gimenez","year":"2024","unstructured":"Garcia-Gimenez JL, Canovas-Cervera I, Pallardo FV. Oxidative stress and metabolism meet epigenetic modulation in physical exercise. Free Radic Biol Med. 2024;213:123\u201337. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2024.01.008.","journal-title":"Free Radic Biol Med"},{"issue":"44","key":"673_CR58","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adq4461","volume":"10","author":"M Fiorenza","year":"2024","unstructured":"Fiorenza M, Onslev J, Henriquez-Olguin C, Persson KW, Hesselager SA, Jensen TE, et al. Reducing the mitochondrial oxidative burden alleviates lipid-induced muscle insulin resistance in humans. Sci Adv. 2024;10(44):eadq4461. https:\/\/doi.org\/10.1126\/sciadv.adq4461.","journal-title":"Sci Adv"},{"issue":"5","key":"673_CR59","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/s41574-019-0156-z","volume":"15","author":"EE Canfora","year":"2019","unstructured":"Canfora EE, Meex RCR, Venema K, Blaak EE. Gut microbial metabolites in obesity, NAFLD and T2DM. Nat Rev Endocrinol. 2019;15(5):261\u201373. https:\/\/doi.org\/10.1038\/s41574-019-0156-z.","journal-title":"Nat Rev Endocrinol"},{"issue":"7","key":"673_CR60","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1038\/s41591-019-0495-2","volume":"25","author":"C Depommier","year":"2019","unstructured":"Depommier C, Everard A, Druart C, Plovier H, Van Hul M, Vieira-Silva S, et al. Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study. Nat Med. 2019;25(7):1096\u2013103. https:\/\/doi.org\/10.1038\/s41591-019-0495-2.","journal-title":"Nat Med"},{"issue":"6","key":"673_CR61","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.chom.2018.05.012","volume":"23","author":"K Makki","year":"2018","unstructured":"Makki K, Deehan EC, Walter J, Backhed F. The impact of dietary fiber on gut microbiota in host health and disease. Cell Host Microbe. 2018;23(6):705\u201315. https:\/\/doi.org\/10.1016\/j.chom.2018.05.012.","journal-title":"Cell Host Microbe"},{"key":"673_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2025.116791","volume":"233","author":"C Xie","year":"2025","unstructured":"Xie C, Qi C, Zhang J, Wang W, Meng X, Aikepaer A, et al. When short-chain fatty acids meet type 2 diabetes mellitus: revealing mechanisms, envisioning therapies. Biochem Pharmacol. 2025;233:116791. https:\/\/doi.org\/10.1016\/j.bcp.2025.116791.","journal-title":"Biochem Pharmacol"},{"issue":"6","key":"673_CR63","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1016\/j.cell.2016.05.041","volume":"165","author":"A Koh","year":"2016","unstructured":"Koh A, De Vadder F, Kovatcheva-Datchary P, Backhed F. From dietary fiber to host physiology: Short-chain fatty acids as key bacterial metabolites. Cell. 2016;165(6):1332\u201345. https:\/\/doi.org\/10.1016\/j.cell.2016.05.041.","journal-title":"Cell"},{"key":"673_CR64","doi-asserted-by":"publisher","DOI":"10.1038\/srep08096","volume":"5","author":"W Jiang","year":"2015","unstructured":"Jiang W, Wu N, Wang X, Chi Y, Zhang Y, Qiu X, et al. Dysbiosis gut microbiota associated with inflammation and impaired mucosal immune function in intestine of humans with non-alcoholic fatty liver disease. Sci Rep. 2015;5:8096. https:\/\/doi.org\/10.1038\/srep08096.","journal-title":"Sci Rep"},{"issue":"21","key":"673_CR65","doi-asserted-by":"publisher","first-page":"9702","DOI":"10.7150\/thno.44297","volume":"10","author":"J Hu","year":"2020","unstructured":"Hu J, Wang H, Li X, Liu Y, Mi Y, Kong H, et al. Fibrinogen-like protein 2 aggravates nonalcoholic steatohepatitis via interaction with TLR4, eliciting inflammation in macrophages and inducing hepatic lipid metabolism disorder. Theranostics. 2020;10(21):9702\u201320. https:\/\/doi.org\/10.7150\/thno.44297.","journal-title":"Theranostics"},{"issue":"4","key":"673_CR66","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1152\/physiolgenomics.00114.2017","volume":"50","author":"N Jiao","year":"2018","unstructured":"Jiao N, Baker SS, Nugent CA, Tsompana M, Cai L, Wang Y, et al. Gut microbiome may contribute to insulin resistance and systemic inflammation in obese rodents: a meta-analysis. Physiol Genomics. 2018;50(4):244\u201354. https:\/\/doi.org\/10.1152\/physiolgenomics.00114.2017.","journal-title":"Physiol Genomics"},{"key":"673_CR67","doi-asserted-by":"publisher","DOI":"10.1016\/j.plipres.2021.101094","volume":"82","author":"S Fiorucci","year":"2021","unstructured":"Fiorucci S, Distrutti E, Carino A, Zampella A, Biagioli M. Bile acids and their receptors in metabolic disorders. Prog Lipid Res. 2021;82:101094. https:\/\/doi.org\/10.1016\/j.plipres.2021.101094.","journal-title":"Prog Lipid Res"},{"key":"673_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2025.107845","volume":"218","author":"M Fan","year":"2025","unstructured":"Fan M, Yang Z, Jin L, Huang W. Differential roles of individual bile acid in physiology and disease. Pharmacol Res. 2025;218:107845. https:\/\/doi.org\/10.1016\/j.phrs.2025.107845.","journal-title":"Pharmacol Res"},{"key":"673_CR69","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.834485","volume":"12","author":"Z Zhou","year":"2022","unstructured":"Zhou Z, Sun B, Yu D, Zhu C. Gut microbiota: an important player in type 2 diabetes mellitus. Front Cell Infect Microbiol. 2022;12:834485. https:\/\/doi.org\/10.3389\/fcimb.2022.834485.","journal-title":"Front Cell Infect Microbiol"},{"issue":"1","key":"673_CR70","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2024.2304157","volume":"16","author":"R Forlano","year":"2024","unstructured":"Forlano R, Martinez-Gili L, Takis P, Miguens-Blanco J, Liu T, Triantafyllou E, et al. Disruption of gut barrier integrity and host-microbiome interactions underlie MASLD severity in patients with type-2 diabetes mellitus. Gut Microbes. 2024;16(1):2304157. https:\/\/doi.org\/10.1080\/19490976.2024.2304157.","journal-title":"Gut Microbes"},{"issue":"5","key":"673_CR71","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.cmet.2022.03.002","volume":"34","author":"Y Liu","year":"2022","unstructured":"Liu Y, Meric G, Havulinna AS, Teo SM, Aberg F, Ruuskanen M, et al. Early prediction of incident liver disease using conventional risk factors and gut-microbiome-augmented gradient boosting. Cell Metab. 2022;34(5):719\u2013e304. https:\/\/doi.org\/10.1016\/j.cmet.2022.03.002.","journal-title":"Cell Metab"},{"issue":"6380","key":"673_CR72","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1126\/science.aao5774","volume":"359","author":"L Zhao","year":"2018","unstructured":"Zhao L, Zhang F, Ding X, Wu G, Lam YY, Wang X, et al. Gut bacteria selectively promoted by dietary fibers alleviate type 2 diabetes. Science. 2018;359(6380):1151\u20136. https:\/\/doi.org\/10.1126\/science.aao5774.","journal-title":"Science"},{"issue":"8","key":"673_CR73","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1111\/liv.13709","volume":"38","author":"MT Long","year":"2018","unstructured":"Long MT, Pedley A, Massaro JM, Hoffmann U, Ma J, Loomba R, et al. A simple clinical model predicts incident hepatic steatosis in a community-based cohort: the Framingham Heart Study. Liver Int. 2018;38(8):1495\u2013503. https:\/\/doi.org\/10.1111\/liv.13709.","journal-title":"Liver Int"},{"issue":"1","key":"673_CR74","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-024-03315-0","volume":"22","author":"L Cao","year":"2024","unstructured":"Cao L, An Y, Liu H, Jiang J, Liu W, Zhou Y, et al. Global epidemiology of type 2 diabetes in patients with NAFLD or MAFLD: a systematic review and meta-analysis. BMC Med. 2024;22(1):101. https:\/\/doi.org\/10.1186\/s12916-024-03315-0.","journal-title":"BMC Med"},{"key":"673_CR75","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2024.111089","volume":"207","author":"Y Wu","year":"2024","unstructured":"Wu Y, Li L, Jiang Y. DM incidence in lean NAFLD. Diabetes Res Clin Pract. 2024;207:111089. https:\/\/doi.org\/10.1016\/j.diabres.2024.111089.","journal-title":"Diabetes Res Clin Pract"},{"issue":"1","key":"673_CR76","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2337\/dsi23-0010","volume":"37","author":"ZM Younossi","year":"2024","unstructured":"Younossi ZM, Henry L. Understanding the burden of nonalcoholic fatty liver disease: time for action. Diabetes Spectr. 2024;37(1):9\u201319. https:\/\/doi.org\/10.2337\/dsi23-0010.","journal-title":"Diabetes Spectr"},{"issue":"10","key":"673_CR77","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1016\/j.cgh.2017.04.045","volume":"15","author":"AL Fracanzani","year":"2017","unstructured":"Fracanzani AL, Petta S, Lombardi R, Pisano G, Russello M, Consonni D, et al. Liver and cardiovascular damage in patients with lean nonalcoholic fatty liver Disease, and association with visceral obesity. Clin Gastroenterol Hepatol. 2017;15(10):1604\u2013e111. https:\/\/doi.org\/10.1016\/j.cgh.2017.04.045.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"Suppl","key":"673_CR78","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.3350\/cmh.2024.0431","volume":"31","author":"ZM Younossi","year":"2025","unstructured":"Younossi ZM, Kalligeros M, Henry L. Epidemiology of metabolic dysfunction-associated steatotic liver disease. Clin Mol Hepatol. 2025;31(Suppl):S32\u201350. https:\/\/doi.org\/10.3350\/cmh.2024.0431.","journal-title":"Clin Mol Hepatol"},{"issue":"4","key":"673_CR79","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1111\/liv.15852","volume":"44","author":"ZM Younossi","year":"2024","unstructured":"Younossi ZM, Golabi P, Paik J, Owrangi S, Yilmaz Y, El-Kassas M, et al. Prevalence of metabolic dysfunction-associated steatotic liver disease in the middle East and North Africa. Liver Int. 2024;44(4):1061\u201370. https:\/\/doi.org\/10.1111\/liv.15852.","journal-title":"Liver Int"},{"issue":"4","key":"673_CR80","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.jhep.2021.05.022","volume":"75","author":"P Golabi","year":"2021","unstructured":"Golabi P, Paik JM, AlQahtani S, Younossi Y, Tuncer G, Younossi ZM. Burden of non-alcoholic fatty liver disease in Asia, the Middle East and North Africa: data from global burden of disease 2009\u20132019. J Hepatol. 2021;75(4):795\u2013809. https:\/\/doi.org\/10.1016\/j.jhep.2021.05.022.","journal-title":"J Hepatol"},{"key":"673_CR81","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14082750","author":"M Pecani","year":"2025","unstructured":"Pecani M, Andreozzi P, Cangemi R, Corica B, Miglionico M, Romiti GF, et al. Metabolic syndrome and liver disease: re-appraisal of screening, diagnosis, and treatment through the paradigm shift from NAFLD to MASLD. J Clin Med. 2025. https:\/\/doi.org\/10.3390\/jcm14082750.","journal-title":"J Clin Med"},{"issue":"4","key":"673_CR82","doi-asserted-by":"publisher","first-page":"884","DOI":"10.5114\/aoms\/150639","volume":"19","author":"B Mitrovic","year":"2023","unstructured":"Mitrovic B, Gluvic ZM, Obradovic M, Radunovic M, Rizzo M, Banach M, et al. Non-alcoholic fatty liver disease, metabolic syndrome, and type 2 diabetes mellitus: where do we stand today? Arch Med Sci. 2023;19(4):884\u201394. https:\/\/doi.org\/10.5114\/aoms\/150639.","journal-title":"Arch Med Sci"},{"key":"673_CR83","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6823-14-9","volume":"14","author":"JV van Vliet-Ostaptchouk","year":"2014","unstructured":"van Vliet-Ostaptchouk JV, Nuotio ML, Slagter SN, Doiron D, Fischer K, Foco L, et al. The prevalence of metabolic syndrome and metabolically healthy obesity in Europe: a collaborative analysis of ten large cohort studies. BMC Endocr Disord. 2014;14:9. https:\/\/doi.org\/10.1186\/1472-6823-14-9.","journal-title":"BMC Endocr Disord"},{"issue":"5","key":"673_CR84","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1111\/cob.12068","volume":"4","author":"M Pallayova","year":"2014","unstructured":"Pallayova M, Taheri S. Non-alcoholic fatty liver disease in obese adults: clinical aspects and current management strategies. Clin Obes. 2014;4(5):243\u201353. https:\/\/doi.org\/10.1111\/cob.12068.","journal-title":"Clin Obes"},{"issue":"47","key":"673_CR85","doi-asserted-by":"publisher","first-page":"8263","DOI":"10.3748\/wjg.v23.i47.8263","volume":"23","author":"BJ Perumpail","year":"2017","unstructured":"Perumpail BJ, Khan MA, Yoo ER, Cholankeril G, Kim D, Ahmed A. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease. World J Gastroenterol. 2017;23(47):8263\u201376. https:\/\/doi.org\/10.3748\/wjg.v23.i47.8263.","journal-title":"World J Gastroenterol"},{"issue":"4 Suppl","key":"673_CR86","doi-asserted-by":"publisher","DOI":"10.5812\/ijem.84792","volume":"16","author":"F Azizi","year":"2018","unstructured":"Azizi F, Takyar M, Zadeh-Vakili A. Contributions and implications of the Tehran lipid and glucose study. Int J Endocrinol Metab. 2018;16(4 Suppl):e84792. https:\/\/doi.org\/10.5812\/ijem.84792.","journal-title":"Int J Endocrinol Metab"},{"issue":"10","key":"673_CR87","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1038\/jhg.2011.87","volume":"56","author":"G Chauhan","year":"2011","unstructured":"Chauhan G, Tabassum R, Mahajan A, Dwivedi OP, Mahendran Y, Kaur I, et al. Common variants of FTO and the risk of obesity and type 2 diabetes in Indians. J Hum Genet. 2011;56(10):720\u20136. https:\/\/doi.org\/10.1038\/jhg.2011.87.","journal-title":"J Hum Genet"},{"issue":"5","key":"673_CR88","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.2337\/db07-1466","volume":"57","author":"RM Freathy","year":"2008","unstructured":"Freathy RM, Timpson NJ, Lawlor DA, Pouta A, Ben-Shlomo Y, Ruokonen A, et al. Common variation in the FTO gene alters diabetes-related metabolic traits to the extent expected given its effect on BMI. Diabetes. 2008;57(5):1419\u201326. https:\/\/doi.org\/10.2337\/db07-1466.","journal-title":"Diabetes"},{"issue":"1","key":"673_CR89","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-019-1364-z","volume":"17","author":"B Namjou","year":"2019","unstructured":"Namjou B, Lingren T, Huang Y, Parameswaran S, Cobb BL, Stanaway IB, et al. GWAS and enrichment analyses of non-alcoholic fatty liver disease identify new trait-associated genes and pathways across eMERGE network. BMC Med. 2019;17(1):135. https:\/\/doi.org\/10.1186\/s12916-019-1364-z.","journal-title":"BMC Med"},{"issue":"4","key":"673_CR90","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1093\/hmg\/ddae184","volume":"34","author":"Z Liu","year":"2025","unstructured":"Liu Z, Chen X, Yuan H, Jin L, Zhang T, Chen X. Dissecting the shared genetic architecture between nonalcoholic fatty liver disease and type 2 diabetes. Hum Mol Genet. 2025;34(4):338\u201346. https:\/\/doi.org\/10.1093\/hmg\/ddae184.","journal-title":"Hum Mol Genet"},{"issue":"12","key":"673_CR91","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1093\/hmg\/ddy124","volume":"27","author":"E Sliz","year":"2018","unstructured":"Sliz E, Sebert S, Wurtz P, Kangas AJ, Soininen P, Lehtimaki T, et al. NAFLD risk alleles in PNPLA3, TM6SF2, GCKR and LYPLAL1 show divergent metabolic effects. Hum Mol Genet. 2018;27(12):2214\u201323. https:\/\/doi.org\/10.1093\/hmg\/ddy124.","journal-title":"Hum Mol Genet"},{"issue":"5","key":"673_CR92","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1007\/s00125-023-05878-8","volume":"66","author":"DS Lee","year":"2023","unstructured":"Lee DS, An TH, Kim H, Jung E, Kim G, Oh SY, et al. Tcf7l2 in hepatocytes regulates de novo lipogenesis in diet-induced non-alcoholic fatty liver disease in mice. Diabetologia. 2023;66(5):931\u201354. https:\/\/doi.org\/10.1007\/s00125-023-05878-8.","journal-title":"Diabetologia"},{"key":"673_CR93","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1050049","volume":"14","author":"Y Tan","year":"2023","unstructured":"Tan Y, He Q, Chan KHK. Identification of shared genetic architecture between non-alcoholic fatty liver disease and type 2 diabetes: a genome-wide analysis. Front Endocrinol (Lausanne). 2023;14:1050049. https:\/\/doi.org\/10.3389\/fendo.2023.1050049.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"673_CR94","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2025.05.031","author":"AJ Sanyal","year":"2025","unstructured":"Sanyal AJ, Taubel J, Badri P, Bond S, Makarova N, Zhao W, et al. Phase 1 randomized double-blind study of an RNA interference therapeutic targeting HSD17B13 for metabolic dysfunction-associated steatohepatitis. J Hepatol. 2025. https:\/\/doi.org\/10.1016\/j.jhep.2025.05.031.","journal-title":"J Hepatol"},{"issue":"10","key":"673_CR95","doi-asserted-by":"publisher","first-page":"3978","DOI":"10.1172\/JCI129186","volume":"129","author":"GI Smith","year":"2019","unstructured":"Smith GI, Mittendorfer B, Klein S. Metabolically healthy obesity: facts and fantasies. J Clin Invest. 2019;129(10):3978\u201389. https:\/\/doi.org\/10.1172\/JCI129186.","journal-title":"J Clin Invest"},{"issue":"10","key":"673_CR96","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1111\/obr.12198","volume":"15","author":"JP Rey-Lopez","year":"2014","unstructured":"Rey-Lopez JP, de Rezende LF, Pastor-Valero M, Tess BH. The prevalence of metabolically healthy obesity: a systematic review and critical evaluation of the definitions used. Obes Rev. 2014;15(10):781\u201390. https:\/\/doi.org\/10.1111\/obr.12198.","journal-title":"Obes Rev"},{"issue":"17","key":"673_CR97","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1016\/j.jacc.2018.02.055","volume":"71","author":"M Mongraw-Chaffin","year":"2018","unstructured":"Mongraw-Chaffin M, Foster MC, Anderson CAM, Burke GL, Haq N, Kalyani RR, et al. Metabolically healthy obesity, transition to metabolic syndrome, and cardiovascular risk. J Am Coll Cardiol. 2018;71(17):1857\u201365. https:\/\/doi.org\/10.1016\/j.jacc.2018.02.055.","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"673_CR98","doi-asserted-by":"publisher","first-page":"2813","DOI":"10.2337\/dc14-0937","volume":"37","author":"J Gomez-Ambrosi","year":"2014","unstructured":"Gomez-Ambrosi J, Catalan V, Rodriguez A, Andrada P, Ramirez B, Ibanez P, et al. Increased cardiometabolic risk factors and inflammation in adipose tissue in obese subjects classified as metabolically healthy. Diabetes Care. 2014;37(10):2813\u201321. https:\/\/doi.org\/10.2337\/dc14-0937.","journal-title":"Diabetes Care"},{"issue":"2","key":"673_CR99","doi-asserted-by":"publisher","first-page":"96","DOI":"10.18544\/PEDM-23.02.0079","volume":"23","author":"Z Zdrojewicz","year":"2017","unstructured":"Zdrojewicz Z, Popowicz E, Szyca M, Michalik T, Smieszniak B. TOFI phenotype - its effect on the occurrence of diabetes. Pediatr Endocrinol Diabetes Metab. 2017;23(2):96\u2013100. https:\/\/doi.org\/10.18544\/PEDM-23.02.0079.","journal-title":"Pediatr Endocrinol Diabetes Metab"},{"issue":"11","key":"673_CR100","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/S2213-8587(15)00291-0","volume":"3","author":"Diabetes Prevention Program Research G","year":"2015","unstructured":"Diabetes Prevention Program Research G. Long-term effects of lifestyle intervention or Metformin on diabetes development and microvascular complications over 15-year follow-up: the diabetes prevention program outcomes study. Lancet Diabetes Endocrinol. 2015;3(11):866\u201375. https:\/\/doi.org\/10.1016\/S2213-8587(15)00291-0.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9702","key":"673_CR101","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1016\/S0140-6736(09)61457-4","volume":"374","author":"G Research","year":"2009","unstructured":"Diabetes Prevention Program, Research G, Knowler WC, Fowler SE, Hamman RF, Christophi CA, Hoffman HJ, et al. 10-year follow-up of diabetes incidence and weight loss in the diabetes prevention program outcomes study. Lancet. 2009;374(9702):1677\u201386. https:\/\/doi.org\/10.1016\/S0140-6736(09)61457-4.","journal-title":"Lancet"},{"issue":"2","key":"673_CR102","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","volume":"149","author":"E Vilar-Gomez","year":"2015","unstructured":"Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, Torres-Gonzalez A, Gra-Oramas B, Gonzalez-Fabian L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology. 2015;149(2):367\u201378. https:\/\/doi.org\/10.1053\/j.gastro.2015.04.005. e5; quiz e14-5.","journal-title":"Gastroenterology"},{"issue":"3","key":"673_CR103","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1007\/s13679-019-00345-1","volume":"8","author":"KT Brunner","year":"2019","unstructured":"Brunner KT, Henneberg CJ, Wilechansky RM, Long MT. Nonalcoholic fatty liver disease and obesity treatment. Curr Obes Rep. 2019;8(3):220\u20138. https:\/\/doi.org\/10.1007\/s13679-019-00345-1.","journal-title":"Curr Obes Rep"},{"issue":"2","key":"673_CR104","doi-asserted-by":"publisher","first-page":"253","DOI":"10.3945\/an.116.013730","volume":"8","author":"CC Hsu","year":"2017","unstructured":"Hsu CC, Ness E, Kowdley KV. Nutritional approaches to achieve weight loss in nonalcoholic fatty liver disease. Adv Nutr. 2017;8(2):253\u201365. https:\/\/doi.org\/10.3945\/an.116.013730.","journal-title":"Adv Nutr"},{"issue":"4","key":"673_CR105","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1053\/j.gastro.2008.06.047","volume":"135","author":"GP Aithal","year":"2008","unstructured":"Aithal GP, Thomas JA, Kaye PV, Lawson A, Ryder SD, Spendlove I, et al. Randomized, placebo-controlled trial of Pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology. 2008;135(4):1176\u201384. https:\/\/doi.org\/10.1053\/j.gastro.2008.06.047.","journal-title":"Gastroenterology"},{"issue":"5","key":"673_CR106","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1001\/jamainternmed.2016.9607","volume":"177","author":"G Musso","year":"2017","unstructured":"Musso G, Cassader M, Paschetta E, Gambino R. Thiazolidinediones and advanced liver fibrosis in nonalcoholic steatohepatitis: a meta-analysis. JAMA Intern Med. 2017;177(5):633\u201340. https:\/\/doi.org\/10.1001\/jamainternmed.2016.9607.","journal-title":"JAMA Intern Med"},{"issue":"5","key":"673_CR107","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1002\/hep.23569","volume":"51","author":"NA Gupta","year":"2010","unstructured":"Gupta NA, Mells J, Dunham RM, Grakoui A, Handy J, Saxena NK, et al. Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway. Hepatology. 2010;51(5):1584\u201392. https:\/\/doi.org\/10.1002\/hep.23569.","journal-title":"Hepatology"},{"issue":"10019","key":"673_CR108","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","volume":"387","author":"MJ Armstrong","year":"2016","unstructured":"Armstrong MJ, Gaunt P, Aithal GP, Barton D, Hull D, Parker R, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016;387(10019):679\u201390. https:\/\/doi.org\/10.1016\/S0140-6736(15)00803-X.","journal-title":"Lancet"},{"issue":"6","key":"673_CR109","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.diabet.2019.12.007","volume":"46","author":"A Mantovani","year":"2020","unstructured":"Mantovani A, Byrne CD, Scorletti E, Mantzoros CS, Targher G. Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: an updated systematic review of randomized controlled trials. Diabetes Metab. 2020;46(6):427\u201341. https:\/\/doi.org\/10.1016\/j.diabet.2019.12.007.","journal-title":"Diabetes Metab"},{"issue":"10215","key":"673_CR110","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","volume":"394","author":"ZM Younossi","year":"2019","unstructured":"Younossi ZM, Ratziu V, Loomba R, Rinella M, Anstee QM, Goodman Z, et al. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2019;394(10215):2184\u201396. https:\/\/doi.org\/10.1016\/S0140-6736(19)33041-7.","journal-title":"Lancet"},{"issue":"21","key":"673_CR111","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.1016\/j.jacc.2018.03.002","volume":"71","author":"BM Everett","year":"2018","unstructured":"Everett BM, Donath MY, Pradhan AD, Thuren T, Pais P, Nicolau JC, et al. Anti-inflammatory therapy with Canakinumab for the prevention and management of diabetes. J Am Coll Cardiol. 2018;71(21):2392\u2013401. https:\/\/doi.org\/10.1016\/j.jacc.2018.03.002.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"673_CR112","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-017-0573-z","volume":"16","author":"A Tenenbaum","year":"2017","unstructured":"Tenenbaum A, Fisman EZ. Mirroring the CANTOS revolution: is anti-inflammatory therapy for diabetes just around the corner? Cardiovasc Diabetol. 2017;16(1):91. https:\/\/doi.org\/10.1186\/s12933-017-0573-z.","journal-title":"Cardiovasc Diabetol"},{"issue":"4","key":"673_CR113","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1002\/hep.29544","volume":"67","author":"O Krenkel","year":"2018","unstructured":"Krenkel O, Puengel T, Govaere O, Abdallah AT, Mossanen JC, Kohlhepp M, et al. Therapeutic Inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis. Hepatology. 2018;67(4):1270\u201383. https:\/\/doi.org\/10.1002\/hep.29544.","journal-title":"Hepatology"},{"issue":"5","key":"673_CR114","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.jhep.2020.05.047","volume":"73","author":"RP Rai","year":"2020","unstructured":"Rai RP, Liu Y, Iyer SS, Liu S, Gupta B, Desai C, et al. Blocking integrin alpha(4)beta(7)-mediated CD4 T cell recruitment to the intestine and liver protects mice from Western diet-induced non-alcoholic steatohepatitis. J Hepatol. 2020;73(5):1013\u201322. https:\/\/doi.org\/10.1016\/j.jhep.2020.05.047.","journal-title":"J Hepatol"},{"issue":"Suppl 1","key":"673_CR115","doi-asserted-by":"publisher","DOI":"10.21037\/atm.2018.10.39","volume":"6","author":"AJ Scheen","year":"2018","unstructured":"Scheen AJ. Effect of sodium-glucose cotransporter type 2 inhibitors on liver fat in patients with type 2 diabetes: hepatic beyond cardiovascular and renal protection? Ann Transl Med. 2018;6(Suppl 1):S68. https:\/\/doi.org\/10.21037\/atm.2018.10.39.","journal-title":"Ann Transl Med"},{"issue":"2","key":"673_CR116","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1001\/jamacardio.2020.4511","volume":"6","author":"DK McGuire","year":"2021","unstructured":"McGuire DK, Shih WJ, Cosentino F, Charbonnel B, Cherney DZI, Dagogo-Jack S, et al. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis. JAMA Cardiol. 2021;6(2):148\u201358. https:\/\/doi.org\/10.1001\/jamacardio.2020.4511.","journal-title":"JAMA Cardiol"},{"key":"673_CR117","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2025.107647","volume":"213","author":"H Li","year":"2025","unstructured":"Li H, Hou Y, Xin W, Ding L, Yang Y, Zhang Y, et al. The efficacy of sodium-glucose transporter 2 inhibitors in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis. Pharmacol Res. 2025;213:107647. https:\/\/doi.org\/10.1016\/j.phrs.2025.107647.","journal-title":"Pharmacol Res"},{"issue":"10","key":"673_CR118","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1038\/s41591-021-01489-1","volume":"27","author":"RA Calle","year":"2021","unstructured":"Calle RA, Amin NB, Carvajal-Gonzalez S, Ross TT, Bergman A, Aggarwal S, et al. ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials. Nat Med. 2021;27(10):1836\u201348. https:\/\/doi.org\/10.1038\/s41591-021-01489-1.","journal-title":"Nat Med"},{"key":"673_CR119","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2022.863834","volume":"9","author":"P Sun","year":"2022","unstructured":"Sun P, Huang L, Shuai P, Wan Z, Liu Y, Xue J. Effect of a high protein, low glycemic index dietary intervention on metabolic dysfunction-associated fatty liver disease: a randomized controlled trial. Front Nutr. 2022;9:863834. https:\/\/doi.org\/10.3389\/fnut.2022.863834.","journal-title":"Front Nutr"},{"issue":"4","key":"673_CR120","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1007\/s12603-016-0809-8","volume":"21","author":"G Misciagna","year":"2017","unstructured":"Misciagna G, Del Pilar Diaz M, Caramia DV, Bonfiglio C, Franco I, Noviello MR, et al. Effect of a low glycemic index mediterranean diet on non-alcoholic fatty liver disease. A randomized controlled clinici trial. J Nutr Health Aging. 2017;21(4):404\u201312. https:\/\/doi.org\/10.1007\/s12603-016-0809-8.","journal-title":"J Nutr Health Aging"},{"issue":"5","key":"673_CR121","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1172\/JCI37385","volume":"119","author":"KL Stanhope","year":"2009","unstructured":"Stanhope KL, Schwarz JM, Keim NL, Griffen SC, Bremer AA, Graham JL, et al. Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight\/obese humans. J Clin Invest. 2009;119(5):1322\u201334. https:\/\/doi.org\/10.1172\/JCI37385.","journal-title":"J Clin Invest"},{"issue":"5","key":"673_CR122","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1080\/10408363.2019.1711360","volume":"57","author":"S Softic","year":"2020","unstructured":"Softic S, Stanhope KL, Boucher J, Divanovic S, Lanaspa MA, Johnson RJ, et al. Fructose and hepatic insulin resistance. Crit Rev Clin Lab Sci. 2020;57(5):308\u201322. https:\/\/doi.org\/10.1080\/10408363.2019.1711360.","journal-title":"Crit Rev Clin Lab Sci"},{"issue":"12","key":"673_CR123","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.2337\/diacare.25.12.2165","volume":"25","author":"Diabetes Prevention Program Research G","year":"2002","unstructured":"Diabetes Prevention Program Research G. The diabetes prevention program (DPP): description of lifestyle intervention. Diabetes Care. 2002;25(12):2165\u201371. https:\/\/doi.org\/10.2337\/diacare.25.12.2165.","journal-title":"Diabetes Care"},{"issue":"5","key":"673_CR124","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1038\/oby.2006.84","volume":"14","author":"ARG Look","year":"2006","unstructured":"Look ARG, Wadden TA, West DS, Delahanty L, Jakicic J, Rejeski J, et al. The look AHEAD study: a description of the lifestyle intervention and the evidence supporting it. Obes (Silver Spring). 2006;14(5):737\u201352. https:\/\/doi.org\/10.1038\/oby.2006.84.","journal-title":"Obes (Silver Spring)"},{"issue":"1","key":"673_CR125","doi-asserted-by":"publisher","DOI":"10.1111\/ijn.13126","volume":"29","author":"Y Han","year":"2023","unstructured":"Han Y, Ye X, Li X, Yang P, Wu Y, Chen L, et al. Comparison of an online versus conventional multidisciplinary collaborative weight loss programme in type 2 diabetes mellitus: a randomized controlled trial. Int J Nurs Pract. 2023;29(1):e13126. https:\/\/doi.org\/10.1111\/ijn.13126.","journal-title":"Int J Nurs Pract"},{"issue":"Suppl 2","key":"673_CR126","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1007\/s12072-024-10663-9","volume":"18","author":"SE Keating","year":"2024","unstructured":"Keating SE, Chawla Y, De A, George ES. Lifestyle intervention for metabolic dysfunction-associated fatty liver disease: a 24-h integrated behavior perspective. Hepatol Int. 2024;18(Suppl 2):959\u201376. https:\/\/doi.org\/10.1007\/s12072-024-10663-9.","journal-title":"Hepatol Int"},{"issue":"8","key":"673_CR127","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1089\/met.2021.0131","volume":"20","author":"MS Thomas","year":"2022","unstructured":"Thomas MS, Blesso CN, Calle MC, Chun OK, Puglisi M, Fernandez ML. Dietary influences on gut microbiota with a focus on metabolic syndrome. Metab Syndr Relat Disord. 2022;20(8):429\u201339. https:\/\/doi.org\/10.1089\/met.2021.0131.","journal-title":"Metab Syndr Relat Disord"},{"key":"673_CR128","doi-asserted-by":"publisher","first-page":"e00398","DOI":"10.1016\/j.plabm.2024.e00398","volume":"40","author":"B Steiner","year":"2024","unstructured":"Steiner B, Leitner C, Stadler D, Prugger EM, Magnes C, Herzog PL. Enzymatic detection of alpha-hydroxybutyrate, an important marker of insulin resistance, and comparison with LC-MS\/MS detection. Pract Lab Med. 2024;40:e00398. https:\/\/doi.org\/10.1016\/j.plabm.2024.e00398.","journal-title":"Pract Lab Med"},{"issue":"11","key":"673_CR129","doi-asserted-by":"publisher","first-page":"2421","DOI":"10.2337\/dc18-1079","volume":"41","author":"MD DeBoer","year":"2018","unstructured":"DeBoer MD, Filipp SL, Gurka MJ. Use of a metabolic syndrome severity Z score to track risk during treatment of prediabetes: an analysis of the diabetes prevention program. Diabetes Care. 2018;41(11):2421\u201330. https:\/\/doi.org\/10.2337\/dc18-1079.","journal-title":"Diabetes Care"},{"key":"673_CR130","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.metabol.2017.01.008","volume":"69","author":"AM Lee","year":"2017","unstructured":"Lee AM, Gurka MJ, DeBoer MD. Correlation of metabolic syndrome severity with cardiovascular health markers in adolescents. Metabolism. 2017;69:87\u201395. https:\/\/doi.org\/10.1016\/j.metabol.2017.01.008.","journal-title":"Metabolism"},{"key":"673_CR131","doi-asserted-by":"publisher","first-page":"2951","DOI":"10.2147\/DMSO.S381146","volume":"15","author":"J Li","year":"2022","unstructured":"Li J, Xu Z, Xu T, Lin S. Predicting diabetes in patients with metabolic syndrome using machine-learning model based on multiple years\u2019 data. Diabetes Metab Syndr Obes. 2022;15:2951\u201361. https:\/\/doi.org\/10.2147\/DMSO.S381146.","journal-title":"Diabetes Metab Syndr Obes"},{"key":"673_CR132","doi-asserted-by":"publisher","first-page":"110047","DOI":"10.1016\/j.diabres.2022.110047","volume":"191","author":"L Daniel Tavares","year":"2022","unstructured":"Daniel Tavares L, Manoel A, Henrique Rizzi Donato T, Cesena F, Andre Minanni C, Miwa Kashiwagi N, et al. Prediction of metabolic syndrome: A machine learning approach to help primary prevention. Diabetes Res Clin Pract. 2022;191:110047. https:\/\/doi.org\/10.1016\/j.diabres.2022.110047.","journal-title":"Diabetes Res Clin Pract"},{"issue":"12","key":"673_CR133","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1080\/14728222.2021.2018418","volume":"25","author":"A Cherubini","year":"2021","unstructured":"Cherubini A, Casirati E, Tomasi M, Valenti L. PNPLA3 as a therapeutic target for fatty liver disease: the evidence to date. Expert Opin Ther Targets. 2021;25(12):1033\u201343. https:\/\/doi.org\/10.1080\/14728222.2021.2018418.","journal-title":"Expert Opin Ther Targets"},{"issue":"5","key":"673_CR134","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1093\/advances\/nmac075","volume":"13","author":"SM Gibbons","year":"2022","unstructured":"Gibbons SM, Gurry T, Lampe JW, Chakrabarti A, Dam V, Everard A, et al. Perspective: leveraging the gut microbiota to predict personalized responses to dietary, prebiotic, and probiotic interventions. Adv Nutr. 2022;13(5):1450\u201361. https:\/\/doi.org\/10.1093\/advances\/nmac075.","journal-title":"Adv Nutr"},{"issue":"1","key":"673_CR135","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1146\/annurev-physiol-022724-105443","volume":"87","author":"RJ Samms","year":"2025","unstructured":"Samms RJ, Kusminski CM. A mechanistic rationale for incretin-based therapeutics in the management of obesity. Annu Rev Physiol. 2025;87(1):279\u201399. https:\/\/doi.org\/10.1146\/annurev-physiol-022724-105443.","journal-title":"Annu Rev Physiol"}],"container-title":["Current Obesity Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13679-025-00673-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13679-025-00673-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13679-025-00673-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T03:57:44Z","timestamp":1763611064000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13679-025-00673-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,20]]},"references-count":135,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["673"],"URL":"https:\/\/doi.org\/10.1007\/s13679-025-00673-5","relation":{},"ISSN":["2162-4968"],"issn-type":[{"value":"2162-4968","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,20]]},"assertion":[{"value":"1 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"During manuscript preparation, the authors employed iFLYTEK Spark (a large language model developed by iFLYTEK Co., Ltd., Hefei, China) for Chinese-to-English translation to refine grammatical structures and improve readability. The AI system operated in interactive mode with default parameters; no output was incorporated without explicit authorial validation. All scientific claims and conclusions presented in this work were independently formulated and remain solely under the authors\u2019 purview. We affirm full accountability for the content\u2019s originality, accuracy, and scholarly integrity.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration of generative AI and AI-assisted technologies in the writing process"}}],"article-number":"81"}}